Maintenance Therapy for Kidney Disease

Introduction

• The Kidney International and American College of Rheumatology guidelines provide recommendations for the management of kidney disease, including vasculitis, with a focus on comprehensive treatment and monitoring 1, 2

Treatment Regimens

• The Kidney International guideline recommends maintenance therapy with Rituximab (500 mg IV every 6 months) or Azatioprina (1.5-2 mg/kg/day) with low-dose glucocorticoids for kidney disease patients 1
• For severe cases, high-dose glucocorticoids such as metilprednisolona IV (500-1000 mg/day) for 3-5 days, followed by oral prednisona with gradual reduction, is recommended 1
• The American College of Rheumatology recommends a combination of glucocorticoids with either cyclophosphamide or rituximab as first-line therapy for vasculitic rash treatment, with the specific choice depending on disease severity and organ involvement 2
• Glucocorticoids + cyclophosphamide is a recommended first-line option, with oral cyclophosphamide dosed at 2 mg/kg/day (maximum 200 mg/day) or IV pulse cyclophosphamide to reduce cumulative dose 2
• Glucocorticoids + rituximab is also a recommended first-line option, particularly effective for ANCA-associated vasculitis 2

Treatment Options Based on Disease Severity

3, 1

Maintenance Therapy

• Azathioprine (1.5-2 mg/kg/day) and methotrexate (20-25 mg/week if creatinine <130 μmol/L) are recommended options for maintenance therapy 2
• Continuing low-dose glucocorticoids (5-7.5 mg/day) for approximately 2 years is recommended, with rituximab 500 mg IV every 6 months as an alternative maintenance option 1, 2
• Methotrexate 20-25 mg/week (if creatinine <130 μmol/L) is another alternative maintenance option, with the duration of maintenance therapy being at least 18 months in patients who remain in complete remission 3, 2, 1, 4

Prevention of Infections

• Trimethoprim/sulfamethoxazole (800/160 mg on alternate days or 400/80 mg daily) is recommended for all patients on cyclophosphamide to prevent infections, as well as for patients with upper respiratory tract disease 3, 2, 1, 4

Monitoring and Assessment

• Regular assessment of clinical response, complete blood count, renal function, electrolytes, and blood pressure is recommended 2
• Re-evaluating diagnosis and optimizing current treatment are recommended, with consideration of alternative agents such as mycophenolate mofetil 2
• Daily monitoring should include weights, intake and output measurements, electrolytes, renal function, and blood pressure to avoid complications such as electrolyte abnormalities, acute kidney injury, hypotension, and metabolic alkalosis 5

Special Considerations

• Patients with ANCA-associated vasculitis should ideally be treated at centers with experience in AAV management, as recommended by the Kidney International guidelines 1
• Consideration of secondary causes of vasculitis, such as drug-induced, infection-associated, and connective tissue disease-associated, is essential, according to the American Journal of Kidney Diseases guidelines 6
• Fertility preservation counseling is essential before treatment initiation, especially for patients of childbearing age, as recommended by the Annals of the Rheumatic Diseases and the Kidney International guidelines 7, 3, 1
• High blood pressure in vasculitis patients should be managed with a combination of immunosuppressive therapy to control the underlying vasculitis and appropriate antihypertensive medications, with calcium channel blockers like amlodipine being preferred first-line agents when renal involvement is present, as recommended by the European Heart Journal and Annals of the Rheumatic Diseases 2, 8
• Comprehensive cardiovascular risk management is necessary for patients with vasculitis, as generally recommended for managing cardiovascular risk, and specifically highlighted by Circulation 9
• Bone protection with osteoporosis prophylaxis should be provided to all patients on glucocorticoids, as recommended by the American College of Rheumatology and the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 10, 1